tldrdailynews.com logo

Insmed Stock Skyrockets on Breakthrough Lung Disease Drug Success

1 min read
Source: Yahoo Finance
Insmed Stock Skyrockets on Breakthrough Lung Disease Drug Success
Photo: Yahoo Finance
TL;DR

Insmed's stock surged 135% after announcing successful Phase 3 trial results for brensocatib in treating non-cystic fibrosis bronchiectasis, showing significant reductions in pulmonary exacerbations. The company plans to file for FDA approval in late 2024, with potential U.S. launch in mid-2025 and subsequent launches in Europe and Japan.

Topics:businessbusinesshealthcare#brensocatib#businesshealthcare#insmed#non-cystic-fibrosis-bronchiectasis#phase-3-study#stock-surge
Share this article
  1. Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday?  Yahoo Finance
  2. Insmed Stock Surges on Trial Win for Lung-Condition Drug, a Possible Blockbuster  Barron's
  3. Insmed CEO on lung disease treatment and path forward  CNBC
  4. Insmed's shares double as lung disease med powers past expectations in phase 3  Fierce Biotech
  5. Insmed Stock Catapults On Its Humira-Like Potential In Lung Disease  Investor's Business Daily

Want the full story? Read the original reporting

Read on Yahoo Finance